Ignite Creation Date:
2024-05-06 @ 3:50 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04777084
Status:
RECRUITING
Last Update Posted:
2023-12-27
First Post:
2021-02-27
Brief Title:
The Efficacy and Safety of the Bispecific Anti-PD-1PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC
Sponsor:
Hunan Province Tumor Hospital
Organization:
Hunan Province Tumor Hospital
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-08-01
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12-25
Completion Date Type:
ESTIMATED
First Submit Date:
2021-02-27
First Submit QC Date:
March 1 2021
Study First Post Date:
2021-03-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-27
Last Update Post Date:
2023-12-27
Last Update Post Date Type:
ACTUAL